Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. - Wikidata - awgldk - TriplyDB

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

http://www.wikidata.org/entity/Q36893329

about

Cancer-induced muscle wasting: latest findings in prevention and treatment.Cancer cachexia-when proteasomal inhibition is not enough.Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival.(Immuno)proteasomes as therapeutic target in acute leukemia.Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.An analysis of the types of recently published research in the field of cachexia.Cachexia therapies - the need to take a broader look.Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018

P2860

Q38681113-76CA02AC-50AC-49DA-95B0-F55065C785E2 Q41852980-C5889440-7320-4877-AF0C-ABC6993365FB Q42155053-AFE1AAB8-5B74-4418-A2E8-A49591D7BB90 Q46213438-A4F718DA-2B01-42D5-AE74-CB9AC76B7824 Q47095769-3075BB17-00E6-403D-A3FB-AE14B5E85873 Q47131929-2FD75B75-6499-401E-94A5-DC244EF9F65B Q47132964-4F2E0534-2679-4A1E-9B60-F1C5E0AD5CB9 Q47568983-BCEEFBF2-4506-48E8-812A-B3341BF877C3 Q49586619-E87D0535-063A-413F-A03C-B375665D7E7B Q51735670-0BBBF64F-FA83-4B6E-BEF8-FF3556BA4250 Q55301138-F1A4D863-DBD3-43BC-AA71-D0E7A306474E Q57458063-29D4AD89-D53D-4061-B9D3-4846B8CB22B8 Q57476138-7037DA9B-73D0-4718-9DD7-CECB8E6AFDC2

P2860

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

http://www.wikidata.org/entity/Q36893329

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

@en

type

label

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

@en

prefLabel

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

@en

P1433

Q36893329-583E2A66-8C38-4BE7-97F1-B3DC0B935CDF

P1476

Q36893329-C945C21C-580D-45C4-93EB-BDF0BCABD17B

P2093

Q36893329-21991B92-58B1-45DA-BCCF-E698C431A04A

Q36893329-D8197B35-BC45-4EA2-85A5-FFE6A19E3D38

Q36893329-EA5F7E67-80D9-4BC1-A889-D1EDF777791D

Q36893329-FA318501-BD60-4877-9690-7A5E482ED6AF

P2860

Q36893329-00617EB4-225D-4C93-B77F-500A155C096E

Q36893329-05FCF9BD-6DE8-40FD-A32E-DC48426F3C98

Q36893329-0C9A858C-7803-4A59-A6F7-7ACD05329AB1

Q36893329-186CCCA8-67F6-4A0F-986C-ED8E845EBFEF

Q36893329-18A9ACA2-DF34-4CB4-A499-3C52880E9728

Q36893329-1C1C2790-BF50-4A6A-941E-4C45F94C11DA

Q36893329-2A7ED095-73D0-4283-BEC8-97F46FC32A4F

Q36893329-2B836B35-4289-4D71-B1EE-82FA8BE53736

Q36893329-2EE06362-1694-4C4B-884D-C46F7B394BC3

Q36893329-33835297-ABFC-453F-9B01-7AAA61902D39

P304

Q36893329-9E7604F8-4ED4-472A-9465-26A3BF8FC10E

P31

Q36893329-1C15A29A-31EC-4FF8-917A-5EFCADC4D094

P356

Q36893329-0EE16216-DF86-4F18-B16D-5BE60E9FA4D5

P433

Q36893329-5908C1A6-F5C8-45B3-A1FA-16363B30CA03

P478

Q36893329-BF9D298D-59F6-4F4A-959B-863B17EE044D

P50

Q36893329-08FBD797-87B4-4525-ADB2-2516727743BE

Q36893329-1D6B2234-9D53-427A-9727-D4917EA4B16E

Q36893329-EE32AF9A-F461-4E43-830D-26C140B788C6

P577

Q36893329-02A91F21-4F1B-4487-BDB1-2D43C1504CD4

P5875

Q36893329-CD28DF29-13B2-4C74-8A8B-EF5273F75BF9

P698

Q36893329-259B2AB8-2E29-4D30-837F-79961F092618

P932

Q36893329-E498B27B-6E00-44CE-BBB8-6A9E43A70630

P356

P1433

Journal of Cachexia, Sarcopenia and Muscle

P1476

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

@en

P2093

Maurizio Muscaritoli

http://www.w3.org/2001/XMLSchema#string

Paola Costelli

http://www.w3.org/2001/XMLSchema#string

Valerio Giacomo Minero

http://www.w3.org/2001/XMLSchema#string

Zaira Aversa

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis

The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond

The ubiquitin-proteasome proteolytic pathway

A phase 2 study of bortezomib in relapsed, refractory myeloma.

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

Cardiotoxicity of the anticancer therapeutic agent bortezomib.

The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice

Treatment of chronic graft-versus-host disease with bortezomib

P304

345-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCSM.12050

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Rossi Fanelli

P577

2015-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282497416

http://www.w3.org/2001/XMLSchema#string

P698

27239411

http://www.w3.org/2001/XMLSchema#string

P932

4864285

http://www.w3.org/2001/XMLSchema#string